Combined focused sequencing assays to identify SSVs, CNAs and FTs in the most commonly altered and/or actionable genes in tumors, along with ulcWGS and IHC staining for PD-L1 and MMRD/MSI, represent a powerful tool to explore additional treatment options in cancer patients with otherwise limited or not well-defined further lines of therapy. This evidence concerns the gene CD274 and cancer.